Team:Oxford/P&P public engagement

From 2014.igem.org

(Difference between revisions)
Line 1: Line 1:
<html>
<html>
<head>
<head>
-
  <meta name="generator" content="HTML Tidy for Linux (vers 25 March 2009), see www.w3.org">
 
   <style type="text/css">
   <style type="text/css">
   @import url(http://fonts.googleapis.com/css?family=PT+Serif|Open+Sans:300italic,400,300);
   @import url(http://fonts.googleapis.com/css?family=PT+Serif|Open+Sans:300italic,400,300);
-
  /* Enforce a lack of horizontal scrollbar so that the social section doesn't mess with the viewport. */
 
   html, body {
   html, body {
     max-width: 100%;
     max-width: 100%;
Line 142: Line 140:
     display: block;
     display: block;
   }
   }
 +
 +
.heading {
 +
    -webkit-transition: margin-left 0.3s, -webkit-transform 0.3s;
 +
    transition: margin-left 0.3s;
 +
}
 +
 +
.heading:hover {
 +
    margin-left:30px;
 +
}
Line 159: Line 166:
.pink_news_block {
.pink_news_block {
        
        
-
         background: #FDDBDB;
+
         background: #DEA5A4;
         border-radius:15px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
         border-radius:15px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
width:96%;
width:96%;
-
}
 
-
.right_news_block {
 
-
     
 
-
        background: #fff;
 
-
        border-radius:15px; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
 
-
width:75%;float:right;line-height:150%;
 
-
}
 
-
.right_news_block2 {
 
-
     
 
-
        background: #fff;
 
-
        border-radius:15px; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
 
-
width:75%;float:right;line-height:150%;margin-top:2%;
 
}
}
Line 201: Line 196:
         background: #FFFF06;
         background: #FFFF06;
         border-radius:30px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:2%;padding-bottom:2%;
         border-radius:30px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:2%;padding-bottom:2%;
-
width:27%;
+
width:100%;
}
}
.white_news_block {
.white_news_block {
Line 215: Line 210:
font-family:Helvetica;
font-family:Helvetica;
margin-bottom: 2%;
margin-bottom: 2%;
-
        line-height:150%;
 
        
        
}
}
Line 223: Line 217:
font-family:Helvetica;
font-family:Helvetica;
         color:#fff;
         color:#fff;
-
        line-height:150%;
 
}
}
h1blue {
h1blue {
Line 254: Line 247:
         line-height:150%;
         line-height:150%;
}
}
-
 
h1black {
h1black {
Line 260: Line 252:
font-weight: 400;
font-weight: 400;
font-family:Helvetica;
font-family:Helvetica;
-
        line-height:150%;
 
}
}
-
h1grey {
 
-
font-size: 280%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#615555;
 
-
        line-height:150%;
 
-
}
 
-
h1purple {
 
-
font-size: 140%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#CE68D5;
 
-
        line-height:150%;
 
-
}
 
-
h2purple {
 
-
font-size: 120%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#CE68D5;
 
-
        line-height:150%;
 
-
}
 
-
h1red {
 
-
font-size: 140%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#B31127;
 
-
        line-height:150%;
 
-
}
 
-
h2red {
 
-
font-size: 120%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#B31127;
 
-
        line-height:150%;
 
-
}
 
-
h1orange {
 
-
font-size: 140%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#F98500;
 
-
        line-height:150%;
 
-
}
 
-
h2orange {
 
-
font-size: 120%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#F98500;
 
-
        line-height:150%;
 
-
}
 
-
h1green {
 
-
font-size: 140%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#0F9101;
 
-
        line-height:150%;
 
-
}
 
-
h2green {
 
-
font-size: 120%;
 
-
font-weight: 400;
 
-
font-family:Helvetica;
 
-
        color:#0F9101;
 
-
        line-height:150%;
 
-
}
 
-
 
   </style>
   </style>
Line 339: Line 266:
 +
#list li {
 +
list-style-image: url("https://static.igem.org/mediawiki/2014/6/6f/OxigemTick.png"); }
 +
}
 +
  </style>
   <script type="text/javascript">
   <script type="text/javascript">
Line 349: Line 280:
$(document).ready(function(){
$(document).ready(function(){
   $("#arrowr").click(function(){
   $("#arrowr").click(function(){
-
     $("#grey").animate({right:'-13%'}, "fast");
+
     $("#grey").animate({right:'-175px'}, "fast");
   });
   });
-
});
 
-
$(document).ready(function(){
 
   $("#arrowl").click(function(){
   $("#arrowl").click(function(){
-
     $("#grey").animate({right:'-9%'}, "fast");
+
     $("#grey").animate({right:'-120px'}, "fast");
 +
  });
 +
  $("#modelling").hover(function(){
 +
    $("#modelling").animate({opacity:'0.95'}, "fast");
 +
    $("#modelling1").css({display:'inline'});
 +
  });
 +
  $("#modelling").mouseout(function(){
 +
    $("#modelling").animate({opacity:'0.75'}, "fast");
 +
    $("#modelling1").css({display:'none'});
 +
  });
 +
  $("#achievements").hover(function(){
 +
    $("#achievements").animate({opacity:'0.95'}, "fast");
 +
    $("#achievements1").css({display:'inline'});
 +
  });
 +
  $("#achievements").mouseout(function(){
 +
    $("#achievements").animate({opacity:'0.75'}, "fast");
 +
    $("#achievements1").css({display:'none'});
 +
  });
 +
  $("#igemcomm").hover(function(){
 +
    $("#igemcomm").animate({opacity:'0.95'}, "fast");
 +
    $("#igemcomm1").css({display:'inline'});
 +
  });
 +
  $("#igemcomm").mouseout(function(){
 +
    $("#igemcomm").animate({opacity:'0.75'}, "fast");
 +
    $("#igemcomm1").css({display:'none'});
 +
  });
 +
  $("#safety").hover(function(){
 +
    $("#safety").animate({opacity:'0.95'}, "fast");
 +
    $("#safety1").css({display:'inline'});
 +
  });
 +
  $("#safety").mouseout(function(){
 +
    $("#safety").animate({opacity:'0.75'}, "fast");
 +
    $("#safety1").css({display:'none'});
 +
  });
 +
  $("#team").hover(function(){
 +
    $("#team").animate({opacity:'0.95'}, "fast");
 +
    $("#team1").css({display:'inline'});
 +
  });
 +
  $("#team").mouseout(function(){
 +
    $("#team").animate({opacity:'0.75'}, "fast");
 +
    $("#team1").css({display:'none'});
 +
  });
 +
  $("#dcmation").hover(function(){
 +
    $("#dcmation").animate({opacity:'0.95'}, "fast");
 +
    $("#dcmation1").css({display:'inline'});
 +
  });
 +
  $("#dcmation").mouseout(function(){
 +
    $("#dcmation").animate({opacity:'0.75'}, "fast");
 +
    $("#dcmation1").css({display:'none'});
 +
  });
 +
  $("#interlab").hover(function(){
 +
    $("#interlab").animate({opacity:'0.95'}, "fast");
 +
    $("#interlab1").css({display:'inline'});
 +
  });
 +
  $("#interlab").mouseout(function(){
 +
    $("#interlab").animate({opacity:'0.75'}, "fast");
 +
    $("#interlab1").css({display:'none'});
 +
  });
 +
  $("#policy").hover(function(){
 +
    $("#policy").animate({opacity:'0.95'}, "fast");
 +
    $("#policy1").css({display:'inline'});
 +
  });
 +
  $("#policy").mouseout(function(){
 +
    $("#policy").animate({opacity:'0.75'}, "fast");
 +
    $("#policy1").css({display:'none'});
   });
   });
 +
});
 +
 +
 +
jQuery(document).ready(function(){
 +
    jQuery('#tb1').live('click', function(event) {       
 +
        jQuery('#b1').toggle('show');
 +
    });
 +
    jQuery('#tb2').live('click', function(event) {       
 +
        jQuery('#b2').toggle('show');
 +
    });
 +
    jQuery('#tb3').live('click', function(event) {       
 +
        jQuery('#b3').toggle('show');
 +
    });
 +
    jQuery('#tb4').live('click', function(event) {       
 +
        jQuery('#b4').toggle('show');
 +
    });
 +
    jQuery('#tb5').live('click', function(event) {       
 +
        jQuery('#b5').toggle('show');
 +
    });
 +
    jQuery('#ts1').live('click', function(event) {       
 +
        jQuery('#s1').toggle('show');
 +
    });
 +
    jQuery('#ts2').live('click', function(event) {       
 +
        jQuery('#s2').toggle('show');
 +
    });
 +
    jQuery('#ts3').live('click', function(event) {       
 +
        jQuery('#s3').toggle('show');
 +
    });
 +
    jQuery('#ts4').live('click', function(event) {       
 +
        jQuery('#s4').toggle('show');
 +
    });
 +
    jQuery('#tg1').live('click', function(event) {       
 +
        jQuery('#g1').toggle('show');
 +
    });
 +
    jQuery('#tg2').live('click', function(event) {       
 +
        jQuery('#g2').toggle('show');
 +
    });
 +
    jQuery('#tg3').live('click', function(event) {       
 +
        jQuery('#g3').toggle('show');
 +
    });
 +
});
 +
 +
 +
function startup(){
 +
  $("#sidebarblue").animate({marginLeft:'+=250px'}, 1000);
 +
  $("#sidebarlogo").animate({marginLeft:'+=250px'}, 1000);
 +
}
 +
function startup1(){
 +
  $(".1").animate({marginLeft:'+=250px'}, 1000);
 +
}
 +
function startup2(){
 +
  $(".2").animate({marginLeft:'+=250px'}, 1000);
 +
}
 +
function startup3(){
 +
  $(".3").animate({marginLeft:'+=250px'}, 1000);
 +
}
 +
function startup4(){
 +
  $(".4").animate({marginLeft:'+=250px'}, 1000);
 +
}
 +
 +
 +
 +
$(document).ready(function(){
 +
  setTimeout(function() {
 +
    startup();
 +
  }, 1500);
 +
  setTimeout(function() {
 +
    startup1();
 +
  }, 1520);
 +
  setTimeout(function() {
 +
    startup2();
 +
  }, 1560);
 +
  setTimeout(function() {
 +
    startup3();
 +
  }, 1640);
 +
  setTimeout(function() {
 +
    startup4();
 +
  }, 1750);
});
});
Line 374: Line 445:
<div style="background-color:#D9D9D9; opacity:0.7; z-index:5; margin-right:auto;margin-left:auto; Height:75px; width:60%;min-width:300px;font-size:65px;font-family:Helvetica;padding-top:5px; font-weight: 450;">
<div style="background-color:#D9D9D9; opacity:0.7; z-index:5; margin-right:auto;margin-left:auto; Height:75px; width:60%;min-width:300px;font-size:65px;font-family:Helvetica;padding-top:5px; font-weight: 450;">
-
<div style="background-color:white; opacity:0.7; Height:75px; width:100%;margin-top:5px:margin-bottom:5px;min-width:300px;font-size:65px;font-family:Helvetica;padding-top:5px; color:#596C8A; font-weight: 450;"><br>Policy & Practices</div>
+
<div style="background-color:white; opacity:0.7; Height:75px; width:100%;margin-top:5px:margin-bottom:5px;min-width:300px;font-size:65px;font-family:Helvetica;padding-top:5px; color:#596C8A; font-weight: 450;"><br>Public Engagement</div>
</div>
</div>
<br><br>
<br><br>
-
<div class="white_news_block">
 
-
<img src="https://static.igem.org/mediawiki/2014/8/8c/Homepage_Diagram.jpg" style="float:left;position:relative; width:21%;" />
 
-
<div class="right_news_block">
 
-
In the emerging field of synthetic biology, iGEM is growing as a source of ambitious and imaginative ideas which have the potential to offer great benefits to human society and our environment. The number of successful iGEM start-ups clearly demonstrates that the competition gives teams the opportunity to get involved in much more than just a summer project; students have the chance to come up with a solution which has a positive impact in the  real world.
 
-
<br>
 
-
In fact, many projects are conceived in the hope of doing just this, often with a specific unresolved social problem in mind. iGEM draws inspiration from the world and the challenges it faces, and contributes back potential solutions.
 
-
<br><br>
 
-
<h1blue>
 
-
"Quote from EA about usefulness of our project/bioremediation/synthetic biology generally, the fact that it could actually help the problem etc…”
 
-
</h1blue>
 
-
 
-
<h1blue2>
 
-
(British Environment Agency)
 
-
</h1blue2>
 
-
 
-
<br><br>
 
-
Our work with the Environment Agency, which inspired us to explore bioremediation as an option for dealing with the pressing environmental concern cause by chlorinated solvent pollution, brought home just how great an impact our own project might have on the in cleaning up this issue. Chlorinated solvents are indispensable to many manufacturing, professional, and even everyday household activities, yet no environmentally acceptable method of disposal currently exists. Our research has led us to believe that bioremediation is a genuinely viable option for addressing this challenge, a position which the Environment Agency has supported. We realized that what began as an iGEM project may well be worth developing further than the months we had to complete the competition.
 
-
<br><br>
 
-
With this in mind, for the policy and practices element of our project we decided to ask…
 
-
</div>
 
-
 
-
 
-
<br><br><br><br><br><br><br><br><br><br><br><br><br>
 
-
<br><br><br><br><br><br><br><br><br><br>
 
-
</div>
 
<div class="white_news_block">
<div class="white_news_block">
-
<h1grey align="center">HOW CAN AN IGEM PROJECT CHANGE THE WORLD?</h1grey>
+
<h1blue2>Focus Groups</h1blue2>
-
</div>
+
 +
Our team hosted a group of volunteers, members of the public with no particular interest or prior experience of biotechnology. Our aim was to gain a deeper understanding of public perceptions and concerns regarding the advance of synthetic biology, and in particular to get an idea of how far these concerns are based on misinformation/lack of understanding, and how far they are legitimate, well-founded fears which need to be addressed by the scientific community as the field grows and develops. If synthetic biology is to become increasingly socially accepted, public participation in it’s growth will be essential.
-
 
-
<div class="white_news_block">
 
-
For the policy and practices element of the competition, our team has researched how iGEM projects grow from ideas into real world solutions. What are the challenges face teams who want to develop their projects beyond the jamboree? What can be done to help them realise the potential benefits of their ideas for society? And what should we be aiming to achieve by all this?
 
-
<br><br>
 
-
Our team identified what we believe are the key considerations for teams to take into account.
 
</div>
</div>
Line 426: Line 467:
-
<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><div class="white_news_block">
 
-
<img src="https://static.igem.org/mediawiki/2014/1/19/Oxford_Environment.png" style="float:left;position:relative; width:6%;margin-right:3%;" />
 
-
<h1blue3>The Goal….</h1blue3>
+
<div class="white_news_block">
-
<br>
+
<h1blue2>8th August 2014 - Round 1</h1blue2>
-
<h2blue3>Many teams are inspired by their search for a synbio solution to a problem or challenge faced by the world. For our team, the need for a way of address the environmental problems caused by chlorinated solvents was clear. Find out more here...</h2blue3>
+
-
</div></a>
 
 +
Our team hosted a group of volunteers, members of the public with no particular interest or prior experience of biotechnology. Our aim was to gain a deeper understanding of public perceptions and concerns regarding the advance of synthetic biology, and in particular to get an idea of how far these concerns are based on misinformation/lack of understanding, and how far they are legitimate, well-founded fears which need to be addressed by the scientific community as the field grows and develops.
 +
Particular issues which appear to be recurring themes in this discussion include:
 +
<br><br>
 +
- Cross-Contamination of 'engineered' genes between synthetic and natural organisms
 +
There is widespread concern that biological machines may evolve, proliferate, and produce unexpected interactions which might alter the ecosystem.
 +
- Use of Bacteria (such as E. coli and P. pseudomonas)
 +
The notion of 'bacteria' generally, and particularly the strains our team plans to use, have strong medical associations and are believed by many to be hazardous to health. E coli is widely understood to cause diarrhea, nausea and vomiting, whilst pseudomonas is best known for causing infections including pneumonia and swimmer's ear.
 +
- Uncontrolled Release of modified organisms into the environment
 +
People have concerns that these will have unpredictable effects on ecosystems and that once taken these actions are difficult if not impossible to reverse. For example, synthetic organisms may outcompete their ‘natural’ counterparts and permanently damage biodiversity.
 +
- Spread of Antibiotic Resistance from synthetic to natural bacteria
 +
Based on vague knowledge that bacteria used in research are generally given characteristics of anti-biotic resistance and that these can spread between organisms.
 +
- Bioterrorism
 +
The public are fearful of the ability of synthetic biology to produce known/modified/new organisms designed to be harmful to humans (as demonstrated, for example, by the synthesis of viruses such as the polio virus and the pandemic Spanish Flu virus and nurtured by Hollywood dramas such as 'Outbreak').
 +
- Creation of 'Artificial Life'
 +
Some of the group expressed fears about scientists 'playing God', explaining their philosophical and religious concerns about the process of creation and the nature of 'living' beings. There was significant confusion as to how exactly 'life' should be defined, where it begins and ends, and what the requisite level of complexity is. Some people vaguely expressed fears that synthetic biology will 'blur' the line between the 'artificial and natural worlds', although did not elaborate on what was meant by this nor why this would be such a negative development.
 +
- Creation of Monopolies
 +
There is some concern that patenting could lead to creation of commercial monopolies and inhibit research. [e.g. BRCA 1 Gene monopoly causing increase in price of testing which could potentially save lives).
 +
- Global Justice
 +
Some of the group expressed worries about the fact that much of the development of synthetic biology and resulting intellectual property is likely to take place in and by extension principally benefit rich, developed nations. Particular examples of this concern which were raised included the possibility of farmers in poor countries becoming dependent on modified crop seeds controlled by large corporations which could extract whatever price they wished for the product, and the possibility of cheap alternatives for manufacture of chemicals such as antimalarial medicine (artemisinin) ensuring that local prodiction of natural equivalent products would no longer be sustained. Generally, this fear is expressed as a concern that technologies which are socially accepted on the premise that they will improve quality of life in less developed countries (golden rice and GM mosquitoes being cited as examples of such projects) may in actual fact benefit only rich Western companies and have no or even a detrimental impact on the lives of those the project was intended to help.
 +
- Lack of Regulation
 +
There is great concern that the development of fast-growing fields such as synthetic biology is 'overtaking' the regulation which is in place to regulate its application and to balance the risks and potential benefits. The possibility of biological warfare programmes is a major worry. A further concern is the possibility of 'garbage biology' (DIY home synthetic biology) may become a more popular, widespread hobby in the future - increased accessibility would make regulations which are in place far more difficult to enforce.
 +
</div>
-
<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><div class="white_news_block">
 
-
<img src="https://static.igem.org/mediawiki/2014/4/43/Oxford_Realisation2.png" style="float:right;position:relative; width:6%;margin-right:3%;" />
 
-
<h1red>Practicality….</h1red>
 
-
<br>
 
-
<h2red>How can the idea be implemented and delivered in the real world? Our engineers used design software and 3D printing to think about how we might realise DCMation and the environments in which the biosensor and bioremediation technique might be used.</h2red>
 
-
</div></a>
 
Line 458: Line 511:
 +
<div class="white_news_block">
-
<a href="https://2014.igem.org/Team:Oxford/P&P_intellectual_property"><div class="white_news_block">
+
<a href="https://2014.igem.org/Team:Oxford/policy_and_practices">
-
<img src="https://static.igem.org/mediawiki/2014/c/c7/Oxford_IP.png" style="float:left;position:relative; width:6%;margin-right:3%;" />
+
<img src="https://static.igem.org/mediawiki/2014/3/33/Oxford_P%26P1.png" style="float:left;position:relative; width:12%;" /></a>
-
<h1purple>Intellectual Property….</h1purple>
+
<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><img src="https://static.igem.org/mediawiki/2014/7/75/Oxford_P%26P2.png" style="float:left;position:relative; width:12%; margin-left:2.66%;" /></a>
-
<br>
+
<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><img src="https://static.igem.org/mediawiki/2014/3/3f/Oxford_P%26P3.png" style="float:left;position:relative; width:12%; margin-left: 2.66%" /></a>
-
<h2purple>Determining the ownership of the intellectual property of a project is crucial for any team hoping to develop their ideas beyond the Jamboree. Our report looks at how the iGEM community can navigate this controversial and difficult issue. </h2purple>
+
-
</div></a>
 
 +
<a href="https://2014.igem.org/Team:Oxford/P&P_intellectual_property"><img src="https://static.igem.org/mediawiki/2014/0/00/Oxford_P%26P4.png" style="float:left;position:relative; width:12%;margin-left: 2.66%;" /></a>
 +
<a href="https://2014.igem.org/Team:Oxford/P&P_communication">
 +
<img src="https://static.igem.org/mediawiki/2014/4/43/Oxford_P%26P5.png" style="float:left;position:relative; width:13%; margin-left: 2.5%" /></a>
 +
<a href="https://2014.igem.org/Team:Oxford/P&P_public_engagement"><img src="https://static.igem.org/mediawiki/2014/3/32/Oxford_P%26P6.png" style="float:left;position:relative; width:12%; margin-left: 2.66%;" /></a>
 +
<a href="https://2014.igem.org/Team:Oxford/P&P_igem_europe">
 +
<img src="https://static.igem.org/mediawiki/2014/9/92/Oxford_P%26P7.png" style="float:right;position:relative; width:12%;" /></a>
 +
<br><br><br><br><br><br><br><br><br>
 +
</div>
 +
</div>
-
<a href="https://2014.igem.org/Team:Oxford/P&P_communication"><div class="white_news_block">
 
-
<img src="https://static.igem.org/mediawiki/2014/c/c5/Oxford_Communication.png" style="float:right;position:relative; width:10%;margin-right:3%;" />
 
-
<h1orange>Communication….</h1orange>
 
-
<br>
 
-
<h2orange>Determining the ownership of the intellectual property of a project is crucial for any team hoping to develop their ideas beyond the Jamboree. Our report looks at how the iGEM community can navigate this controversial and difficult issue. </h2orange>
 
-
</div></a>
 
Line 501: Line 556:
-
<a href="https://2014.igem.org/Team:Oxford/P&P_public_engagement"><div class="white_news_block">
 
-
<img src="https://static.igem.org/mediawiki/2014/c/c6/Oxford_public.png" style="float:left;position:relative; width:6%;margin-right:3%;" />
 
-
<h1blue3>Public Participation….</h1blue3>
 
-
<br>
 
-
<h2blue3>
 
-
Determining the ownership of the intellectual property of a project is crucial for any team hoping to develop their ideas beyond the Jamboree. Our report looks at how the iGEM community can navigate this controversial and difficult issue.
 
-
</h2blue3>
 
-
</div></a>
 
Line 525: Line 572:
-
<a href="https://2014.igem.org/Team:Oxford/P&P_igem_europe"><div class="white_news_block">
 
-
<img src="https://static.igem.org/mediawiki/2014/e/e5/Oxford_europe.png" style="float:right;position:relative; width:10%;margin-right:3%;" />
 
-
<h1green>The iGEM Competition….</h1green>
 
-
<br>
 
-
<h2green>
 
-
iGEM has been steadily expanding since its beginnings in 2004, climbing from 5 to over 200 teams in the last 10 years. As the first ever Oxford team, we are more than a little late to the party! Our team has researched the growing contribution made by the rest of Europe to the competition, of which we hope to become a part from 2014 onwards!
 
-
</h2green>
 
-
</div></a>
 
Line 548: Line 587:
 +
<div id="sponsors" style="height:10%; width:100%;"></div>
-
 
+
     
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
<div class="white_news_block">
+
-
 
+
-
 
+
-
 
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/policy_and_practices">
+
-
<img src="https://static.igem.org/mediawiki/2014/3/33/Oxford_P%26P1.png" style="float:left;position:relative; width:12%;" /></a>
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><img src="https://static.igem.org/mediawiki/2014/7/75/Oxford_P%26P2.png" style="float:left;position:relative; width:12%; margin-left:2.66%;" /></a>
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><img src="https://static.igem.org/mediawiki/2014/3/3f/Oxford_P%26P3.png" style="float:left;position:relative; width:12%; margin-left: 2.66%" /></a>
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/P&P_intellectual_property"><img src="https://static.igem.org/mediawiki/2014/0/00/Oxford_P%26P4.png" style="float:left;position:relative; width:12%;margin-left: 2.66%;" /></a>
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/P&P_communication">
+
-
<img src="https://static.igem.org/mediawiki/2014/4/43/Oxford_P%26P5.png" style="float:left;position:relative; width:13%; margin-left: 2.5%" /></a>
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/P&P_public_engagement"><img src="https://static.igem.org/mediawiki/2014/3/32/Oxford_P%26P6.png" style="float:left;position:relative; width:12%; margin-left: 2.66%;" /></a>
+
-
 
+
-
<a href="https://2014.igem.org/Team:Oxford/P&P_igem_europe">
+
-
<img src="https://static.igem.org/mediawiki/2014/9/92/Oxford_P%26P7.png" style="float:right;position:relative; width:12%;" /></a>
+
-
 
+
-
<br><br><br><br><br><br><br><br><br>
+
-
</div>
+
</div>
</div>
 +
<img id="sidebarblue" src="https://static.igem.org/mediawiki/2014/e/ec/OxigemsidebarBlue.png" style="float:left;position:fixed;margin-left:-250px;height:100%;" />
 +
<img class="1" src="https://static.igem.org/mediawiki/2014/a/a5/OxigemDotsDCMation.png" style="opacity:0.9;float:left;position:fixed;margin-left:-250px; top:31.6%; height:17.6%;" />
 +
<img class="2" src="https://static.igem.org/mediawiki/2014/0/06/OxigemDotsinterlab.png" style="opacity:0.9;float:left;position:fixed;margin-left:-250px; top:18.3%; height:15.125%;" />
 +
<img class="3" src="https://static.igem.org/mediawiki/2014/e/ee/OxigemDotsP%26P.png" style="opacity:0.9;float:left;position:fixed;margin-left:-250px; top:9%; height:12.75%;" />
 +
<img class="4" src="https://static.igem.org/mediawiki/2014/c/ca/OxigemDotsTeam.png" style="float:left;position:fixed;margin-left:-250px; top:0%; height:12.625%;" />
 +
<img class="1" src="https://static.igem.org/mediawiki/2014/f/f5/OxigemDotsModelling.png" style="opacity:0.8;float:left;position:fixed;margin-left:-250px; top:50.6%; height:17.75%;" />
 +
<img class="2" src="https://static.igem.org/mediawiki/2014/8/87/OxigemDotsAchievements.png" style="opacity:0.9;float:left;position:fixed;margin-left:-250px; top:66.45%; height:13.28%;" />
 +
<img class="3" src="https://static.igem.org/mediawiki/2014/7/7b/OxigemDotsiGEMcomm.png" style="opacity:0.9;float:left;position:fixed;margin-left:-250px; top:78%; height:12.5%;" />
 +
<img class="4" src="https://static.igem.org/mediawiki/2014/0/0e/OxigemDotsSafety.png" style="float:left;position:fixed;margin-left:-250px; top:88.15%; height:11.9%;" />
 +
<a href="https://2014.igem.org/Team:Oxford"><img id="sidebarlogo" class="oxigem" src="https://static.igem.org/mediawiki/2014/a/a4/Oxigemsidebarlogo.png" style="float:left;position:fixed;margin-left:-250px; top:42.5%; height:15%;"/></a>
 +
<img src="https://static.igem.org/mediawiki/2014/3/37/OxigemDotModelling.png" style="float:left;position:fixed; top:59.3%; height:4.125%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/0/05/OxigemDotAchievements.png" style="float:left;position:fixed; top:71%; height:4%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/7/77/OxigemDotiGEMcomm.png" style="float:left;position:fixed; top:81.5%; height:4.375%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/2/27/OxigemDotSafety.png" style="float:left;position:fixed; top:93%; height:4.125%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/e/e7/OxigemDotDCMation.png" style="float:left;position:fixed; top:37%; height:4.125%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/9/94/OxigemDotInterlab.png" style="float:left;position:fixed; top:25%; height:4.125%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/1/19/OxigemDotP%26P.png" style="float:left;position:fixed; top:13.5%; height:4.375%;" />
 +
<img src="https://static.igem.org/mediawiki/2014/c/cc/OxigemDotTeam.png" style="float:left;position:fixed; top:3%; height:4.375%;" />
 +
<img id="modelling1" src="https://static.igem.org/mediawiki/2014/9/93/OxigemDotModelling1.png" style="display:none;float:left;position:fixed; top:59.3%; height:4.125%;" />
 +
<img id="achievements1" src="https://static.igem.org/mediawiki/2014/0/0f/OxigemDotAchievements1.png" style="display:none;float:left;position:fixed; top:71%; height:4%;" />
 +
<img id="igemcomm1" src="https://static.igem.org/mediawiki/2014/a/a8/OxigemDotiGEMcomm1.png" style="display:none;float:left;position:fixed; top:81.5%; height:4.375%;" />
 +
<img id="safety1" src="https://static.igem.org/mediawiki/2014/e/ee/OxigemDotSafety1.png" style="display:none;float:left;position:fixed; top:93%; height:4.125%;" />
 +
<img id="dcmation1" src="https://static.igem.org/mediawiki/2014/d/db/OxigemDotDCMation1.png" style="display:none;float:left;position:fixed; top:37%; height:4.125%;" />
 +
<img id="interlab1" src="https://static.igem.org/mediawiki/2014/5/52/OxigemDotInterlab1.png" style="display:none;float:left;position:fixed; top:25%; height:4.125%;" />
 +
<img id="policy1" src="https://static.igem.org/mediawiki/2014/b/bf/OxigemDotP%26P1.png" style="display:none;float:left;position:fixed; top:13.5%; height:4.375%;" />
 +
<img id="team1" src="https://static.igem.org/mediawiki/2014/c/c5/OxigemDotTeam1.png" style="display:none;float:left;position:fixed; top:3%; height:4.375%;" />
 +
<a href="#"><img class="heading" id="modelling" src="https://static.igem.org/mediawiki/2014/e/e0/OxigemSidebarModelling.png" style="opacity:0.8;float:left;position:fixed; top:59%; height:4.5%;"  /></a>
 +
<a href="#"><img class="heading" id="achievements" src="https://static.igem.org/mediawiki/2014/4/4a/OxigemSidebarAchievements.png" style="opacity:0.75;float:left;position:fixed; top:71%; height:4%;" /></a>
 +
<a href="#"><img class="heading" id="igemcomm" src="https://static.igem.org/mediawiki/2014/8/83/OxigemSidebariGEMcomm.png" style="opacity:0.8;float:left;position:fixed; top:81.1%; height:5.375%;" /></a>
 +
<a href="https://2014.igem.org/Team:Oxford/safety"><img class="heading" id="safety" src="https://static.igem.org/mediawiki/2014/3/3d/OxigemSidebarSafety.png" style="opacity:0.75;float:left;position:fixed; top:92.9%; height:4.375%;" /></a>
 +
<a href="#"><img class="heading" id="dcmation" src="https://static.igem.org/mediawiki/2014/1/18/OxigemSidebarDCMation.png" style="opacity:0.8;float:left;position:fixed; top:36%; height:5.75%;" /></a>
 +
<a href="#"><img class="heading" id="interlab" src="https://static.igem.org/mediawiki/2014/e/e2/OxigemSidebarInterlab.png" style="opacity:0.8;float:left;position:fixed; top:24.4%; height:5.25%;" /></a>
 +
<a href="https://2014.igem.org/Team:Oxford/policy_and_practices"><img class="heading" id="policy" src="https://static.igem.org/mediawiki/2014/7/7b/OxigemSidebarP%26P.png" style="opacity:0.8;float:left;position:fixed; top:13.2%; height:4.875%;" /></a>
 +
<a href="https://2014.igem.org/Team:Oxford/team"><img class="heading" id="team" src="https://static.igem.org/mediawiki/2014/3/3b/OxigemSidebarTeam.png" style="opacity:0.8;float:left;position:fixed; top:3%; height:4.625%;" /></a>
Line 626: Line 637:
-
 
+
<img src="https://static.igem.org/mediawiki/2014/6/60/OxigemAchievements2.png" style="position:fixed; display:none; height:4%; top:37%; left:2%;" />
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
<div id="sponsors" style="height:200px; width:100%;"></div>
+
-
 
+
-
</div>
+
-
 
+
-
 
+
-
 
+
-
 
+
-
<img src="https://static.igem.org/mediawiki/2014/9/91/OxigemSidebar.png" style="float:left;position:fixed; height:100%;" />
+
-
 
+
   <div class="iGEMlogo" style="width:6.5%; position:absolute; top:0.7%; right:0.5%; min-width:50px;">
   <div class="iGEMlogo" style="width:6.5%; position:absolute; top:0.7%; right:0.5%; min-width:50px;">
-
     <a href="https://2014.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2014/9/98/OxigemiGEM.png" style="width:100%"/></a>
+
     <a href="https://2014.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2014/5/56/OxigemiGEMgrey.png" style="width:100%"/></a>
   </div>
   </div>
-
   <a href="#"><img id="arrowl" src="https://static.igem.org/mediawiki/2014/7/77/OxigemArrowl.png" style="position:absolute; width:2.5%; top:50%;right:1.5%; opacity:0.6; z-index:4;" /></a>
+
   <a href="#"><img id="arrowl" src="https://static.igem.org/mediawiki/2014/1/1d/OxigemArrowleft.png" style="position:fixed; width:50px; top:23%;right:0px; opacity:0.6; z-index:4;" /></a>
-
   <div id="grey" style="width:14%; position:absolute; top:23%; right:-13%; z-index:4;">
+
   <div id="grey" style="width:190px; position:fixed; top:23%; right:-175px; z-index:4;">
     <img src="https://static.igem.org/mediawiki/2014/0/0d/OxigemGrey.png" style="position:relative;width:100%;" />
     <img src="https://static.igem.org/mediawiki/2014/0/0d/OxigemGrey.png" style="position:relative;width:100%;" />
-
     <a href="#"><img id="arrowr" src="https://static.igem.org/mediawiki/2014/0/03/OxigemArrowr.png" style="position:absolute;width:16%;top:5%;left:10%;"></a>
+
     <a href="#"><img id="arrowr" src="https://static.igem.org/mediawiki/2014/0/03/OxigemArrowr.png" style="position:absolute;width:14%;top:5%;left:10%;"></a>
     <div class="fbicon" style="position:absolute;width:23%; top:20%; left:9%;" onmouseover=
     <div class="fbicon" style="position:absolute;width:23%; top:20%; left:9%;" onmouseover=
       "iconleft(this)" onmouseout="iconnormal(this)" border="0"><a href="https://www.facebook.com/oxfordigem" target="_blank" style="background-image: none;"><img src="https://static.igem.org/mediawiki/2014/8/88/OxigemIconfacebook.png" style="width:100%;" /></a>
       "iconleft(this)" onmouseout="iconnormal(this)" border="0"><a href="https://www.facebook.com/oxfordigem" target="_blank" style="background-image: none;"><img src="https://static.igem.org/mediawiki/2014/8/88/OxigemIconfacebook.png" style="width:100%;" /></a>

Revision as of 08:09, 20 September 2014

#list li { list-style-image: url("https://static.igem.org/mediawiki/2014/6/6f/OxigemTick.png"); } }


Public Engagement


Focus Groups Our team hosted a group of volunteers, members of the public with no particular interest or prior experience of biotechnology. Our aim was to gain a deeper understanding of public perceptions and concerns regarding the advance of synthetic biology, and in particular to get an idea of how far these concerns are based on misinformation/lack of understanding, and how far they are legitimate, well-founded fears which need to be addressed by the scientific community as the field grows and develops. If synthetic biology is to become increasingly socially accepted, public participation in it’s growth will be essential.
8th August 2014 - Round 1 Our team hosted a group of volunteers, members of the public with no particular interest or prior experience of biotechnology. Our aim was to gain a deeper understanding of public perceptions and concerns regarding the advance of synthetic biology, and in particular to get an idea of how far these concerns are based on misinformation/lack of understanding, and how far they are legitimate, well-founded fears which need to be addressed by the scientific community as the field grows and develops. Particular issues which appear to be recurring themes in this discussion include:

- Cross-Contamination of 'engineered' genes between synthetic and natural organisms There is widespread concern that biological machines may evolve, proliferate, and produce unexpected interactions which might alter the ecosystem. - Use of Bacteria (such as E. coli and P. pseudomonas) The notion of 'bacteria' generally, and particularly the strains our team plans to use, have strong medical associations and are believed by many to be hazardous to health. E coli is widely understood to cause diarrhea, nausea and vomiting, whilst pseudomonas is best known for causing infections including pneumonia and swimmer's ear. - Uncontrolled Release of modified organisms into the environment People have concerns that these will have unpredictable effects on ecosystems and that once taken these actions are difficult if not impossible to reverse. For example, synthetic organisms may outcompete their ‘natural’ counterparts and permanently damage biodiversity. - Spread of Antibiotic Resistance from synthetic to natural bacteria Based on vague knowledge that bacteria used in research are generally given characteristics of anti-biotic resistance and that these can spread between organisms. - Bioterrorism The public are fearful of the ability of synthetic biology to produce known/modified/new organisms designed to be harmful to humans (as demonstrated, for example, by the synthesis of viruses such as the polio virus and the pandemic Spanish Flu virus and nurtured by Hollywood dramas such as 'Outbreak'). - Creation of 'Artificial Life' Some of the group expressed fears about scientists 'playing God', explaining their philosophical and religious concerns about the process of creation and the nature of 'living' beings. There was significant confusion as to how exactly 'life' should be defined, where it begins and ends, and what the requisite level of complexity is. Some people vaguely expressed fears that synthetic biology will 'blur' the line between the 'artificial and natural worlds', although did not elaborate on what was meant by this nor why this would be such a negative development. - Creation of Monopolies There is some concern that patenting could lead to creation of commercial monopolies and inhibit research. [e.g. BRCA 1 Gene monopoly causing increase in price of testing which could potentially save lives). - Global Justice Some of the group expressed worries about the fact that much of the development of synthetic biology and resulting intellectual property is likely to take place in and by extension principally benefit rich, developed nations. Particular examples of this concern which were raised included the possibility of farmers in poor countries becoming dependent on modified crop seeds controlled by large corporations which could extract whatever price they wished for the product, and the possibility of cheap alternatives for manufacture of chemicals such as antimalarial medicine (artemisinin) ensuring that local prodiction of natural equivalent products would no longer be sustained. Generally, this fear is expressed as a concern that technologies which are socially accepted on the premise that they will improve quality of life in less developed countries (golden rice and GM mosquitoes being cited as examples of such projects) may in actual fact benefit only rich Western companies and have no or even a detrimental impact on the lives of those the project was intended to help. - Lack of Regulation There is great concern that the development of fast-growing fields such as synthetic biology is 'overtaking' the regulation which is in place to regulate its application and to balance the risks and potential benefits. The possibility of biological warfare programmes is a major worry. A further concern is the possibility of 'garbage biology' (DIY home synthetic biology) may become a more popular, widespread hobby in the future - increased accessibility would make regulations which are in place far more difficult to enforce.